Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?

J Natl Compr Canc Netw. 2020 Jan;18(1):113-114. doi: 10.6004/jnccn.2019.7523.
No abstract available

MeSH terms

  • Biomarkers
  • Drug Approval
  • Humans
  • Neoplasms*
  • Pharmaceutical Preparations*
  • Precision Medicine
  • United States
  • United States Food and Drug Administration

Substances

  • Biomarkers
  • Pharmaceutical Preparations